Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole Long-term Extension in MDD
NCT01944969Phase 3Terminated
- Sponsor
- Lundbeck
- Start
- Oct 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events at 52 weeks and Number of Withdrawals at 52 weeks. Started Oct 2013; status: terminated.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01944969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01944969.